Surfactant-associated protein 3 (SFTA3)

Surfactant-associated protein 3 (SFTA3), also known as surfactant protein H (SP-H), is a secretory protein originally identified by bioinformatics analysis and primarily expressed in the human lung and ocular surface[1][3][5]. SFTA3 is part of the surfactant gene family but shows no significant sequence or structural similarity with other known surfactant proteins[1][5]. It is proposed to be an amphiphilic protein with properties influenced by post-translational modifications such as palmitoylation, glycosylation, and phosphorylation, which allow it to localize to lipid membranes and modulate surface tension[5]. SFTA3 is implicated in immune defense at mucosal surfaces, particularly in the lungs, functioning in the regulation of surface tension and providing protective effects during inflammation[3][5]. The expression of SFTA3 is upregulated in the presence of bacterial components such as lipopolysaccharide but inhibited by inflammatory cytokines like IL-1β and IL-23[3][1]. Recent studies also support its role in promoting wound healing in ocular tissues and potential involvement in the pathophysiology of dry eye disease, where SFTA3 levels are increased[1]. SFTA3 does not currently have evidence supporting a role as a direct therapeutic target (such as enzyme, transporter, receptor, or transcription factor) and has no known drug interactions or established mechanism of drug action[1][3][5]. While described as a "pulmonary arterial hypertension related factor" in some contexts, there is no evidence that it is directly targeted in any current pharmaceutical or clinical applications.

Other names

Surfactant protein HSP-HSFTPHSurfactant-associated protein HNKX2.1 associated non-coding intergenic RNApulmonary arterial hypertension related factorNANCIPAHRF